Myblu vaping products will not be allowed to be sold in the US market while a court reviews a marketing denial order (MDO).
An appeal court has declined to issue an emergency stay for Fontem US in its challenge to an MDO issued by the US Food and Drug Administration (FDA). The decision is a defeat for the maker of the Myblu vaping pod that could have greater implications for it as it pursues its full court challenge, with a panel of three judges determining that it “has not made a strong showing that it is likely to succeed on the merits”.
Get access to premium content that is normally only available for subscribers.
For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the ECigIntelligence team.